VRCA Revisited 9M Later, Post FDA Approval

Wanted to revisit a post I made last year about VRCA. See Post history around 250ish days ago. While it played out nicely earlier this year, anyone who held through approvals got cooked. This seems to happen a lot these days with small bios. I have been accumulating shares around $5 and will keep adding with some call options for a few months out. Looking at options for 5 and 7.5c out past the next earnings report. I am intrigued by this play because it’s currently rocking an almost 18% short interest and 8 DTC. Insider ownership is slightly up to 40% (CEO just purchased a mil worth at $5.02) and tutes hold another 31%. This narrows the float to only 17M. They have credit and cash runway into 2025, so no risk of dilution. This coupled with recent approval and pricing / sales catalyst make this a good fundamental and maybe squeeze play. The r/r seems right at this level around $5 to start loading. looking for the same price level as my original post, with potential squeezy upside of $10+. Just needs a catalyst and volume. They should be providing cost and estimated earnings for their approval product this month and rollout of product for sale next month. Short volume has been 60-80% since approval. It’s very suspect and I believe will eventually blow back the other way, as downside from here seems nominal. I’ll plan to have a stop around $4.50, which is fairly tight but anything under $5 is squeezing blood from a stone. There is no real reason to trade much lower, unless they fail the product launch. However that should be hard to screw up as they have the only FDA approved drug to treat MC. But we shall see. Currently 1500 shares at $5.28. Adding slowly at anything under that.